Surgical Strategies and Chemotherapy Options

Treating advanced ovarian cancer requires a highly coordinated effort between specialized surgeons (gynecologic oncologists) and medical oncologists. The “gold standard” for treatment involves a combination of surgery and chemotherapy.

The Goal: Complete Cytoreduction

For advanced disease, the primary surgical goal is achieving complete cytoreduction (often called R0), which means having no macroscopic (visible) tumor remaining at the end of surgery ^[1].

Important Clarification: Even when a surgeon achieves “R0” and removes all visible tumors, microscopic cancer cells usually remain behind in the abdomen. This is exactly why systemic chemotherapy is almost always required after surgery—to “mop up” these invisible cells and prevent immediate recurrence.

Two Paths to One Goal

There are two primary ways your medical team will approach your treatment. Both have been shown to lead to similar survival outcomes, so the choice often depends on your overall health, surgical fitness, and the extent of the cancer ^[2].

Path 1: Primary Debulking Surgery (PDS)

This path involves having major surgery first, followed by chemotherapy.

• When it is used: If the surgeon believes they can remove all visible disease and you are healthy enough for a major operation ^[2].

Path 2: Neoadjuvant Chemotherapy (NACT) and Interval Surgery

This path involves a few cycles of chemotherapy first to shrink the tumor, followed by surgery (Interval Debulking Surgery or IDS), and then more chemotherapy ^[2].

• When it is used: If the tumor is too extensive to remove completely at first, or if you have comorbidities that make immediate surgery risky ^[3][4].
• The Advantage: Research shows NACT is noninferior to PDS for survival but is associated with lower perioperative morbidity and mortality, making the surgery safer for many patients ^[5][6].

The Standard Chemotherapy “Backbone”

Regardless of which path you take, the standard chemotherapy for ovarian cancer is a combination of a platinum drug (like carboplatin) and a taxane (like paclitaxel).

While these drugs are highly effective at damaging cancer cell DNA and stopping cell division, they come with immediate acute physical side effects. Patients commonly experience hair loss, severe nausea, bone pain, fatigue, and neuropathy (numbness or tingling in the hands and feet).

Do not suffer in silence. Modern oncology has excellent interventions to manage these side effects, including powerful anti-nausea medications, dose adjustments, and scalp-cooling (cold-capping) to help preserve hair. Speak to your medical oncologist early and often about symptom management.

(Note: If your tumor testing reveals a specific feature called Mismatch Repair deficiency [MMR] or MSI-High, your doctor may also discuss incorporating immunotherapy—drugs that help your own immune system fight the cancer ^[7].)

What is HIPEC?

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is an advanced technique where a heated chemotherapy solution is circulated inside the abdomen during surgery. In combination with interval cytoreductive surgery, it has shown potential to improve survival outcomes in selected patients with stage III disease ^[8][9].

The Reality of HIPEC: It is critical to understand that HIPEC is a grueling procedure with a tough recovery. It carries risks of kidney toxicity, severe fatigue, and significant gastrointestinal issues. Your doctor must help you carefully weigh these intense physical tolls against the potential benefits.

Vetting Your Care Team

Ovarian cancer surgery is complex and often involves operating on multiple organs to achieve R0. Do not hesitate to ask your surgeon how many of these procedures they perform each year. A multidisciplinary approach, ideally at a specialized center with experienced gynecologic oncologists, is critical for your outcome.